Woodline Partners LP Keros Therapeutics, Inc. Transaction History

Woodline Partners LP

$10.5 Billion
Q1 2024

A detailed history of Woodline Partners LP transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 761,700 shares of KROS stock, worth $34.8 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares

761,700

Previous 583,792 30.47%

Holding current value

$34.8 Million

Previous $23.2 Million 117.24%

% of portfolio

0.48%

Previous 0.26%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$41.26 - $70.48 $7.34 Million - $12.5 Million	177,908 Added 30.47%	761,700 $50.4 Million
Q4 2023 Feb 14, 2024	SELL	$27.12 - $41.05 $3.65 Million - $5.53 Million	-134,631 Reduced 18.74%	583,792 $23.2 Million
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $13.9 Million - $18.9 Million	438,722 Added 156.85%	718,423 $22.9 Million
Q2 2023 Aug 14, 2023	BUY	$37.26 - $51.01 $3.04 Million - $4.16 Million	81,562 Added 41.16%	279,701 $11.2 Million
Q1 2023 May 15, 2023	BUY	$41.44 - $59.32 $59,673 - $85,420	1,440 Added 0.73%	198,139 $8.46 Million

Q4 2022 Feb 14, 2023	SELL	$39.45 - $51.77 $5.75 Million - $7.55 Million	-145,794 Reduced 42.57%	196,699 $9.45 Million
Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $9.52 Million - $13.7 Million	342,493 New	342,493 $12.9 Million
Q2 2022 Aug 15, 2022	SELL	$26.03 - $67.04 $6.69 Million - $17.2 Million	-257,200 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $7.62 Million - $10.7 Million	180,988 Added 237.48%	257,200 $14 Million
Q4 2021 Feb 14, 2022	SELL	$36.95 - $62.89 $4.12 Million - $7.02 Million	-111,623 Reduced 59.43%	76,212 $4.46 Million
Q3 2021 Nov 15, 2021	BUY	$29.27 - $43.71 $5.5 Million - $8.21 Million	187,835 New	187,835 $7.43 Million

Others Institutions Holding KROS

# of Institutions

153

Shares Held

26.7M

Call Options Held

47.6K

Put Options Held

34.5K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Keros Therapeutics, Inc. Transaction History